Same molecule — semaglutide — made by the same company. Different doses, different FDA approvals, different insurance coverage, and very different price tags. Here's exactly how they compare.
Both Ozempic and Wegovy are semaglutide — the exact same active molecule, made by Novo Nordisk. The difference is dose and FDA approval: Ozempic (0.5–2mg weekly) is approved for type 2 diabetes (2017), while Wegovy (2.4mg weekly) is approved for chronic weight management (2021). Same GLP-1 receptor mechanism. Same side effect profile. Different insurance criteria, different cost, and Wegovy's higher dose produces greater average weight loss.
| Factor | 🔵 Ozempic | 🟣 Wegovy |
|---|---|---|
| FDA Approval | Type 2 diabetes (Dec 2017); CV risk reduction (2020) | Chronic weight management / obesity (Jun 2021) |
| Active Ingredient | Semaglutide | Semaglutide |
| Weekly Dose Range | 0.25mg (starter) → 0.5mg → 1mg → 2mg (max) | 0.25mg (starter) → up to 2.4mg (maintenance max) |
| Maintenance Dose | 0.5–2mg weekly | 2.4mg weekly |
| Who It's For | Adults with type 2 diabetes; also reduces heart attack/stroke risk | Adults with BMI ≥30, or BMI ≥27 with weight-related condition |
| Average Weight Loss | ~5–7% body weight (SUSTAIN trials at diabetes doses) | ~15% body weight at 68 weeks (STEP 1 trial, 2.4mg) |
| A1c Reduction | ~1.5–1.8% at 1mg; ~1.9% at 2mg (SUSTAIN 1–5) | Reduces A1c but not primary endpoint; ~1.6% in STEP 2 (T2D) |
| Cash Cost (No Insurance) | ~$900–$950/month | ~$1,350–$1,400/month |
| Insurance Coverage | Commonly covered for T2D diagnosis; prior auth often required | Variable; Medicare Part D covers only if CVD risk; many plans exclude weight drugs |
| Manufacturer Savings Card | Ozempic savings card: as low as $25/month (commercially insured) | Wegovy savings offer: as low as $25/month (commercially insured, income limits) |
| Availability (2026) | Generally available; occasional regional shortages | Improved since 2024 shortage; check pharmacy stock |
| Pen Device | FlexTouch pen (green); multi-dose | Auto-injector pen; single-dose |
| Manufacturer | Novo Nordisk | Novo Nordisk |
Semaglutide is a GLP-1 receptor agonist — a synthetic version of glucagon-like peptide-1, a hormone your gut releases after meals. It binds to GLP-1 receptors throughout the body: in the pancreas, brain, heart, gut, and liver.
The primary effects that make semaglutide valuable for two different conditions are:
Why dose matters so much: At lower doses (0.5–1mg), the blood sugar effects dominate — useful for diabetes management with moderate weight reduction as a secondary benefit. At 2.4mg, the appetite-suppression effects at the hypothalamic level become much stronger, producing the 15% average weight loss seen in the STEP trials. More semaglutide = more GLP-1 receptor activation = more pronounced hunger reduction.
Novo Nordisk didn't invent two different drugs — they optimized one drug for two patient populations by studying dose-response relationships and seeking separate FDA approvals. This is common in pharmaceutical development; the same active ingredient at different doses can have meaningfully different clinical profiles.
FDA approved December 2017 for glycemic control in adults with type 2 diabetes, with cardiovascular risk reduction added as an indication in 2020 following the SUSTAIN-6 cardiovascular outcomes trial.
Ozempic starts at 0.25mg weekly for 4 weeks (a tolerability dose, not a therapeutic dose), then steps up:
The SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) trial program (SUSTAIN 1–10+) demonstrated A1c reductions of ~1.5–1.9% versus placebo, with consistent cardiovascular benefit in SUSTAIN-6 (26% reduction in major adverse cardiovascular events vs placebo). The 2mg dose showed improved A1c reduction compared to 1mg without new safety signals.
Notably, Ozempic is not FDA-approved for weight loss, even though significant weight loss is a consistent side effect. Doctors can and do prescribe it off-label for weight management, but this affects insurance coverage dramatically.
FDA approved June 2021 — the first GLP-1 receptor agonist approved specifically for chronic weight management. A second approval came in March 2024, making Wegovy the first weight loss medication approved to reduce cardiovascular risk (SELECT trial).
Wegovy's maintenance dose of 2.4mg weekly is higher than Ozempic's maximum of 2mg. The escalation schedule is also longer — 16 weeks to reach full maintenance dose — designed to minimize GI side effects during dose increases:
STEP 1 (non-diabetic adults, BMI ≥30): 2.4mg semaglutide produced 14.9% average weight loss at 68 weeks vs 2.4% placebo. STEP 2 (adults with T2D): 9.6% weight loss. STEP 3 (intensive behavioral support): 16.0%. STEP 4 (maintenance): confirmed regain when drug stopped. These results established Wegovy as the most effective non-surgical weight loss treatment at the time of approval.
This is where the Ozempic vs Wegovy difference becomes most practically important for most patients.
Most commercial insurance plans and Medicare Part D cover Ozempic for type 2 diabetes with prior authorization. Prior auth typically requires: documented T2D diagnosis, A1c above threshold, trial of metformin (often required first), and prescriber documentation. Once approved, copays can be $0–$50/month with coverage.
Coverage is significantly more variable. Many commercial plans exclude weight loss medications entirely. The AOM Coverage Act (proposed, not yet law as of mid-2026) would expand Medicare coverage. Some employer plans added coverage after 2022. Medicare Part D covers Wegovy only for the cardiovascular risk reduction indication (established CVD). Check your specific plan's formulary — call the number on your insurance card and ask specifically about Wegovy coverage.
Telehealth workaround: Several telehealth platforms prescribe Ozempic off-label for weight loss at cash prices sometimes lower than retail pharmacy. Compounded semaglutide (which was widely available during the 2022–2024 shortage) is now prohibited for most pharmacies following FDA's March 2024 shortage resolution declaration. Be cautious of any service still offering "compounded Ozempic" — verify legality with the dispensing pharmacy.
The right choice depends primarily on your medical situation and insurance coverage. Here's a practical decision framework:
While you're working through the insurance and prescription process, these research-backed supplements and tools can support your health goals.
Berberine, chromium, and other supplements studied for blood sugar regulation are commonly used as complementary support alongside GLP-1 medication or while waiting for insurance approval. Look for clinical-grade formulations with transparent dosing.
Shop Blood Sugar Support →Tracking weight loss progress on semaglutide is most meaningful when you can distinguish fat loss from muscle loss. Smart body composition scales measure body fat percentage, muscle mass, and visceral fat — giving you a clearer picture than weight alone.
Shop Body Composition Scales →